Chinese Nasdaq-like market, Star Market, is attracting another healthcare company. Neusoft Medical is looking forward to an IPO fundraising for tomography development.
► The biggest Chinese CT provider is about to hit the Star Market.
► Compared to its peers, Neusoft Medical has a lot to do in terms of R&D and selling model.
As one of the subsidiaries of Neusoft Group – a Chinese healthcare IT solution provider – Neusoft Medical recently applied to go public on Star Market. Unlike the parent company, which is listed on the A-share market, Neusoft Medical has chosen to go public on Star Market for a fundraising amount close to CNY 965.08 million.
According to the prospectus, Neusoft Medical plans to utilize the raised funds to facilitate research projects for the core products, technology and equipment and establish distribution channels, boost brand development and training systems.
To be listed on the Star Market, the company picked the listing rule that the estimated market value shall be over CNY 1 billion and the net profit of the last year higher than CNY 100 million. Neusoft Medical’s prospectus discloses that its net profits were CNY 11.68 million, CNY 82.76 million and CNY 35.13 million from 2017 to 2019. However, it still faces the risk of IPO failure – if the market value at the issuance date does not reach the IPO requirement (over CNY 1 billion).
Business strength: A comprehensive product portfolio
Neusoft Medical is a tier-one medical equipment manufacturer. It is mainly engaged in the R&D, production, distribution and related solutions circling the core product portfolio, covering computed tomography (CT), magnetic resonance imaging (MRI), digital subtraction angiography (DSA), general X-ray (GXR), Ultrasound (US), positron emission tomography and computed tomography (PET/CT), radiation therapy (RT) and in vitro diagnostic (IVD).
Known as one of the few medical equipment providers that owns comprehensive imaging and diagnostics equipment, Neusoft Medical has expanded its business to over 100 countries and regions, including over 80 markets in the coverage of the One Belt One Road project.
Since 2017, the company has developed a more balanced business structure, as the digital medical diagnostic equipment business represented a fallen share from 74.82% in 2017 to 65% in 2019. Meanwhile, the equipment service and training business has been growing – from 16.82% in 2017 to 25.20% in 2019 – which indicates it is more focused on establishing a long-term customer relationship.
The three years also saw a twisted path for the company's net margin, from 3.57% in 2017, 8.76% in 2018 to 4.29% in 2019. In the abnormal year 2018, the company sold out a medical incubation center as an intangible asset at a price of over CNY 52.5 million. The proceeds were recorded as part of the total CNY 59.66 million extraordinary operating profits, which account for 3.1% of the entire 2018 revenue.
The Chinese medical devices industry is experiencing a limelight phase, with an increasing number of new policies launching intensively and making heavy capital injections. Local Chinese brand companies are sparing no effort in utilizing the golden time.
The National Medical Products Administration shows that the Chinese medical device companies amounted to 18,699 in 2018 from 16,169 in 2014, at a CAGR of 3.7%. Faced with fierce competition from foreign peers in terms of product technology and service quality, Chinese players need to find their niche competitiveness.
Neusoft Medical engages in an extensive range of digital imaging equipment, supplementing activities with compatible post-sale services. With substantial industry experience in CT equipment, now it has become the most prominent Chinese manufacturer in this field. As of the end of 2019, the company and its subsidiaries had delivered all kinds of medical diagnostic equipment for over 38.000 units.
According to the company's prospectus, there are a total of nine competitors Neusoft Medical is directly facing, including four foreign players and five Chinese brands. A clear advantage is that Neusoft has the most comprehensive portfolio, with eight product lines, while none of the other Chinese companies can do that. GE Medical and Siemens medical are the only two most similar in terms of the product coverage – indeed, they represent a combined 53.5 % Chinese market share of the CT scanners.
When it comes to the topic of investability, Neusoft Medical can be compared with three Chinese public companies – Wandong Medical (600055:SH), Mindray Medical (300760:SZ) and SonoScape Medical (300633:SZ).
In terms of the selling expense ratio over total revenue, the last three years saw a general trend in Wandong, Mindray and Neusoft, except SonoScape, which grew over 5%.
As for the R&D investment, Neusoft had the highest ratio against the revenue, as high as 22.03%, a nearly doubled rate of the industry average. The most expensive medical device company Mindray Medical only had 10.13%, and SonoScape and Wandong Medical have 19.18% and 8.14% each.
However, to have a better understanding of this ratio, it is crucial to reference the other two perspectives, R&D capitalization and pipeline diversity.
During the last three years, Neusoft has maintained an R&D capitalization rate of approximately 12% – 14%, while recording an expense ratio of 8.5% – 11%. An increase in the capitalization R&D indicates higher efficiency in converting R&D input into potentially profitable assets.
The other perspective on the above-industry-average R&D investment concerns the product pipeline diversity. Neusoft has the most comprehensive product coverage; the R&D investment ratio per product type averages at 2.4%. Wandong and Mindray can reach 3.57% and 2.95% in terms of R&D investment per product line.
The long path after the public debut
There is a long path ahead of Neusoft Medical. Maybe in the long-term future, Neusoft may take on an expansion path similar to Mindray, which spent the first few years acquiring growing companies inbound and outbound.
However, it may face a more significant risk coming from goodwill impairment. The company recorded a loss of over CNY 23.55 million in goodwill impairment loss in 2018 and CNY 8.92 in 2019.
More than that, it also faces risks from bad debts. It recorded a loss of CNY 6.96 million in the failure of collecting accounts receivables. In 2019, Neusoft had lower receivables turnover 1.54x than the average of the three comparables mentioned above: Wandong Medical 1.31x, SonoScape 3.37x and Mindray 9.89x. Even though the company explains that this is because Neusoft adopts an installment-charging mode, the considerable gap indicates that it has a relatively weaker voice in the downstream distribution side.